Asana Biosciences, LLC

Epix Pharmaceuticals, Inc.

Microdose Therapeutx, Inc.

Other

Praecis Pharmaceuticals, Inc.

Endo Pharmaceuticals Inc.

Pic Therapeutics, Inc.

Galenea Corp.

Abs Development 1, Inc.

Endo Pharmaceuticals Solutions Inc.

Ashis K Saha

Scott Kevin Thompson

Tony Priestley

Oren Becker

Yael Marantz

Aranapakam Mudumbai Venkatesan

Sharon Shacham

Mrinal Kundu

Pini Orbach

Srinivasa Rao Cheruku

Mercedes Lobera

Dilara McCauley

Xiang Y Yu

Anurag Sharadendu

Mrinalkanti Kundu

Suvadeep Nath

Roger Astbury Smith

Jian Lin

Silvia Noiman

Zhaoda Zhang

Nili Schutz

Sonali Rudra

Vincent Jacques

Dale S Dhanoa

Sandeep Gupta

Hanoch Senderowitz

Nicholas James Laping

Merav Fichman

Rosa Melendez

A Sekar Reddy

Efrat Ben-Zeev

Robert Christian Penland

Kimberley Gannon

Michael Xie

Barry A Morgan

Victor J Cee

Hui-Yin Li

Brian Alan Lanman

Jennifer Elizabeth Golden

Roland W Burli

Malcolm J Kavarana

Carl Henry Behrens

Susana C Neira

Laurence Wu

Ghotas Evindar

Laurence I Wu

Yigang He

Dilârâ McCauley

Alexander L Satz

Roland Burli

Dipanwita Chatterjee

Arun Kuma Hajra

Scott Thompson

Rosa E Melendez

Dilara Mccaulay

Susana Neira

Robert C Penland

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

P2X3 and/or P2X2/3 compounds and methods

The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with eIF4E. Such diseases, disorders, or conditions include cellular proliferative disorders (e.g., cancer) such as those described herein.

EIF4E inhibitors and uses thereof

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

P2Xand/or P2Xcompounds and methods

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient. 

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R-Rare defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2Xor P2Xreceptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. 

[object Object]

Provided are adenosine analog compounds such as that act as P2Y receptors, e.g., the P2Yreceptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.

Adenosine analogs and their use

The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine. 

Cyclohexylamines

The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine. 

Aminoindane compounds and use thereof in treating pain

Growing community of inventors

Stow, MA, United States of America

Ashis K Saha